Crossref
We will not have to wait—building regulatory confidence in early endpoints for high-risk breast cancer
AME Clinical Trials Review · 2026-06 · 4 · 28-28
DOI: 10.21037/actr-25-123 ↗Kurz gefasst
Fachartikel in der Zeitschrift AME Clinical Trials Review, 2026-06. Verfasst von Keli Santos-Parker und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Santos-Parker, K., & Esserman, L. (2026). We will not have to wait—building regulatory confidence in early endpoints for high-risk breast cancer. AME Clinical Trials Review, 4, 28-28. https://doi.org/10.21037/actr-25-123
Vancouver
Santos-Parker K, Esserman L. We will not have to wait—building regulatory confidence in early endpoints for high-risk breast cancer. AME Clinical Trials Review. 2026;4:28-28. doi:10.21037/actr-25-123
BibTeX
@article{SantosParker2026,
author = {Santos-Parker, Keli and Esserman, Laura},
title = {We will not have to wait—building regulatory confidence in early endpoints for high-risk breast cancer},
journal = {AME Clinical Trials Review},
year = {2026},
volume = {4},
pages = {28--28},
doi = {10.21037/actr-25-123}
}
EUVIMED